Zyden Gentec Ltd Stock Analysis

BSE: 530091 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - Make an Informed Decision on Zyden Gentec

M-Cap below 100cr DeciZen not available

Zyden Gentec Price Chart

P/E Ratio (SA) :
Market Cap :
4.8 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Zyden Gentec Ltd. a good quality company?

Data is not available for this company.

2. Is Zyden Gentec Ltd. undervalued or overvalued?

No data found

3. Is Zyden Gentec Ltd. a good buy now?

No data found

10 Year X-Ray of Zyden Gentec:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

ROCE % 3.7%3.3%-14.9%-1.9%-1%-0.1%1.7%-0.1%-2.4%-12.9%-
Value Creation Index -0.7-0.8-2.1-1.1-1.1-1.0-0.9-1.0-1.2-1.9-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 17.512.
YoY Gr. Rt. %--30.9%-21.4%-20.6%-78.9%-78.6%5.9%-86.1%1,380%55.4%-
Adj EPS 0-0-0.7-0.1-0.1-00.10-0.3-0.3-0.7
YoY Gr. Rt. %--200%NANANANANA-100%NANA-
BVPS (₹)
Adj Net Profit 0.1-0.1-4.1-0.7-0.300.30-1.5-1.4-4
Cash Flow from Ops. 4-1.6-
Debt/CF from Ops. 1-6.2-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -26.1%-6.3%47.3%55.4%
Adj EPS -223.1%NA-263%NA
BVPS -11.9-13.5-20.5-38.6
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 1.3-1.2-36.9-5.7-2-0.32.8-0.1-14.2-18.2-39.3
Op. Profit Mgn % 4.29.7-30.5-13.4-81.1-115.589.2-24.248-37.70
Net Profit Mgn % 0.6-0.9-43-9.7-15.9-12.296.3-24.6-207.5-125.1-328.5
Debt to Equity
Working Cap Days 1833385437713,36615,09915,8511,05,0657,4023,6410
Cash Conv. Cycle 1011522011879743,505-6,60,63624,4271,8618890

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Zyden Gentec Ltd.

Standalone Consolidated
TTM EPS (₹) -0.7 0.1
TTM Sales (₹ Cr.) 1.2 0
BVPS (₹.) 2.4 2.4
Reserves (₹ Cr.) 2 2
P/BV 0.37 0.36
PE 0.00 8.56
From the Market
52 Week Low / High (₹) 0.87 / 0.95
All Time Low / High (₹) 0.16 / 35.80
Market Cap (₹ Cr.) 4.8
Equity (₹ Cr.) 11.1
Face Value (₹) 2
Industry PE 37

Management X-Ray of Zyden Gentec :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *58.420.
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Zyden Gentec

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Zyden Gentec Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Zyden Gentec on 01-Jan-1970 05:30 is : 0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Zyden Gentec stood at ₹ 4.83.
The latest PE ratio of Zyden Gentec as of 01-Jan-1970 05:30 is 0.00.
The latest PB ratio of Zyden Gentec as of 01-Jan-1970 05:30 is 0.37
The 52-week high of Zyden Gentec is ₹ 0.95 and the 52-week low is ₹ 0.87.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Zyden Gentec is ₹ 1.15 ( Cr.) .

About Zyden Gentec Ltd

Zyden Gentec was incorporated on April 26, 1994 under the companies Act 1956 as Overseas Capital Private Limited. The name of the company was changed to Overseas Capital Limited on conversion into public limited company on November 11, 1994 and to Zyden Gentec Limited on July 16, 2004. The company was promoted by RK Dhar.

Initially the company was engaged in providing financial services and is presently engaged in the manufacturing of pharmaceuticals and fine chemicals.

Product range of the company includes:

The company's principal activity is to manufacture pharmaceutical products and to provide concultancy services. The company operates in two segments namely Manufacturing & Allied Activities and Financial, Investment & Allied Activities. The products of the company include specialized chemicals, bulk drugs, compounds and intermediates

  • Drotaverine HCL
  • Levocetrizine
  • Ketoconazole
  • Sildenafil Citrate
  • Glucosamine
  • Ciprofloxacin HCL
  • Enro Floxacin
  • Bypyridine
  • Guaifenesin
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now